Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

2.490 +0.220 (+9.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Black Diamond Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM
Black Diamond Therapeutics has announced encouraging initial data from a Phase 1 study of BDTX-1535, an investigational fourth-generation EGFR MasterKey 
Via Spotlight Growth
Black Diamond Therapeutics Inc. (NASDAQ: BDTX) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Changes to Board of Directors
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.